Website intended for a NZ health professional readership
Linda Bryant discusses gout, a chronic long-term condition that is often associated with other diseases, and drug-related morbidity and mortality. As such, gout needs to be addressed holistically as part of the psychosocial medical model
1. Health Quality & Safety Commission New Zealand. Atlas of Healthcare Variation: Gout. 2021. https://tinyurl.com/HQSCgout
2. Dalbeth N, House ME, Horne A, et al. The experience and impact of gout in Māori and Pacific people: a prospective observational study. Clin Rheum 2013;32(2):247–51.
3. Ministry of Health. Pharmaceutical Collection. People starting preventative gout medication for the first time between 1 June 2016 and 30 June 2020 aged 15+ years. https://tinyurl.com/hlthstats
4. Dalbeth N, Dowell T, Gerard C, et al. Gout in Aotearoa New Zealand: the equity crisis continues in plain sight. N Z Med J 2018;131(1485):8–12.
5. Gill I, Dalbeth N, Ofanoa M, et al. Interventions to improve uptake of urate-lowering therapy in patients with gout: A systematic review. BJGP Open 2020;4(3): bjgpopen20X101051.
6. Choi HK, Curhan G. Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study. BMJ 2008;336(7639):309–12.
7. Hueskes B, Roovers E, Mantel-Teeuwisse A, et al. Use of diuretics and the risk of gouty arthritis: a systematic review. Semin Arthritis Rheum 2012;41(6):879–89.
8. Zhang Y, Neogi T, Chen C, et al. Low-dose aspirin use and recurrent gout attacks. Ann Rheum Dis 2014;73(2):385–90.
9. Stamp LK, Barclay ML, O'Donnell JL, et al. Furosemide increases plasma oxypurinol without lowering serum urate--a complex drug interaction: implications for clinical practice. Rheumatology (Oxford) 2012;51(9):1670–76.
10. Choi HK, Ford ES, Li C, et al. Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2007;57(1):109–15.
11. Stamp LK, Chapman PT. Gout and its comorbidities: implications for therapy. Rheumatology (Oxford) 2013;52(1):34–44.
12. Choi HK, Curhan G. Independent impact of gout on mortality and risk for coronary heart disease. Circulation 2007;116(8):894–900.
13. Liu X, Sun D, Ma X, et al. Benefit-risk of corticosteroids in acute gout patients: An updated meta-analysis and economic evaluation. Steroids 2017;128:89–94.
14. Roddy E, Clarkson K, Blagojevic-Bucknall M, et al. Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care. Ann Rheum Dis 2020;79(2):276–84.
15. Jayaprakash V, Ansell G, Galler D. Colchicine overdose: the devil is in the detail. N Z Med J 2007;120:U2402.
16. Tomlin A, Woods DJ, Lambie A, et al. Ethnic inequality in non-steroidal anti-inflammatory drug-associated harm in New Zealand: A national population-based cohort study. Pharmacoepidemiol Drug Saf 2020;29(8):881–89.
17. BPACnz. Managing gout in primary care. August 2021. https://bpac.org.nz/2021/docs/gout2021.pdf
18. Harrold LR, Andrade SE, Briesacher BA, et al. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther 2009;11(2):R46.
19. Eminaga F, Le-Carratt J, Jones A, et al. Does the initiation of urate-lowering treatment during an acute gout attack prolong the current episode and precipitate recurrent attacks: a systematic literature review. Rheumatol Int 2016;36(12):1747–52.
20. FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken) 2020; 72(6):744–60.
21. Borstad G, Bryant L, Abel M, et al. Colchicine for prophylaxis of acute flares when initiating allopurinol for gouty arthritis. J Rheumatol 2004.31(12):2429–32.
22. Stamp L, Taylor W, Jones P, et al. Starting dose is a risk factor for allopurinol hypersensitivity syndrome. Arthritis Rheum 2012;64(8):2529–36.
23. A. Menarini New Zealand Pty Ltd. New Zealand Datasheet: Adenuric® 80 mg, 120 mg film coated tablets. August 2019. medsafe.govt.nz
24. Soffer BA, Wright JT Jr, Pratt JH, et al. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995;26(1):112–17.
25. Ohshiro K, Sakima A, Nakada S, et al. Beneficial effect of switching from a combination of angiotensin II receptor blockers other than losartan and thiazides to a fixed dose of losartan/hydrochlorothiazide on uric acid metabolism in hypertensive patients. Clin Exp Hypertens 2011;33(8):565–70.
In this article, Sue Frankland looks at the global problem of wastage of medications, including causes such as overprescribing and non-adherence. She also presents information from her master’s dissertation on how people understand, and respond to, medication expiration dates
Why recognising the signs of dehydration is important...
